RLMD Earning Date, Earning Analysis and Earning Prediction

Quarterly Results

RLMD Earnings Forecast

Looking ahead, RLMD remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of undefined and an EPS of -0.04.

However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been unchanged by 0%, while EPS estimates have been revised upward by 47.45%. For the upcoming , revenue estimates have been adjusted unchanged by 0%. These revisions correlate with a 0% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in RLMD long-term fundamentals.

The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

RevenueEPS

Currency: USD

Revenue Estimate-:0

EPS Estimate-:0

—

Stock Price0

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+47.45%

In Past 3 Month

Earnings Forecast

Revenue

EPS

Currency:

No data

Actual

Estimate

AI Analysis

Earnings Surprise Analysis

Revenue

EPS

AI Analysis

Earnings Reaction

The chart below shows how RLMD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RLMD sees a -1.31% change in stock price 10 days leading up to the earnings, and a 3.86% change 10 days following the report. On the earnings day itself, the stock moves by -1.94%. This data can give you a slight idea of what to expect for the next quarter's release.

For example, in SEP/2025, the stock changed 1.8% on the day following the earnings release and then changed by 16.24% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

People Also Watch

Frequently Asked Questions

What were the key highlights of RLMD's latest earnings report for ?

RLMD reported its earnings on 2025-11-13, showcasing a revenue of 0.00 against an estimate of , resulting in a 0% surprise. The EPS was -0.3, surpassing the expected -0.04 by -650%. The stock experienced a 1.8% price change on the earnings day and a 7.73% change over the next five days, reflecting market reactions to the results.

How did RLMD's stock price react after the earnings release?

Following RLMD's earnings announcement on 2025-11-13, the stock price moved by 1.8% on the day of the release. Over the subsequent five days, it saw a 7.73% change. Historically, RLMD's stock price tends to shift by an average of -1.31% in the 10 days leading up to earnings and 3.86% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for RLMD for ?

For , analysts estimate RLMD's annual revenue to reach undefined, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

How does RLMD's stock price correlate with earnings forecast revisions?

The correlation between RLMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from RLMD's next earnings report?

Based on historical trends, RLMD's stock price typically moves by -1.31% in the 10 days before its earnings and 3.86% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.04 and revenue of undefined.

What is the sentiment in Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Summary?

The earnings call presents a mixed picture: strong financial backing and strategic plans for NDV-01 and sepranolone, but with notable risks in supply chain and financial management. The Q&A section highlights uncertainties, particularly regarding compliance with FDA requirements and market adoption challenges. Despite a positive cash position and reduced R&D expenses, the increase in net loss and operational costs raises concerns. The lack of clear guidance on FDA expectations and market strategy tempers enthusiasm, leading to a neutral stock price prediction.